Business
Positive top line phase I results for Acarovac MPL
Positive top line phase I results for Acarovac MPL.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 4837Z Allergy Therapeutics PLC 20 May 2019 \n\n \n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Group\")\n \nAllergy Therapeutics announces positive top line results from Phase I clinical study using Acarovac MPL\n \n- Investigational house dust mite allergy vaccine demonstrates good safety and tolerability profile \n- Patients experienced symptom improvement in response to Nasal Provocation Testing \n \n20 May 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces positive Phase I safety and tolerability results of subcutaneous Acarovac MPL (Monophosphoryl Lipid A) in patients with house dust mite (HDM)-induced allergic rhinoconjunctivitis. The AM101 trial was an open-label study to assess the safety and tolerability of Acarovac MPL in 16 adult patients with house dust mite-mediated allergic rhinoconjunctivitis. \n \nThe primary endpoint was the safety and tolerability of 7 injections of Acarovac MPL administered over 6-12 weeks each 1-2 weeks apart. The formulation was well tolerated. The safety profile was satisfactory and the reported adverse events were consistent with what have been observed with similar formulations of allergy vaccines.\n \nSecondary endpoints included the effect of treatment on response to nasal provocation test (NPT), immunological parameters including immunoglobulins and patients' satisfaction with the treatment. A significant improvement from baseline in patients' total symptom scores following NPT after 12 weeks, and significant increases in immunoglobulin markers and reduction in IL-4 were observed. Patients reported high satisfaction with their treatment measured via the ESPIA questionnaire (Satisfaction Scale for Patients Receiving Allergen Immunotherapy). \n \nManuel Llobet, Chief Executive Officer of Allergy Therapeutics, said: \"The success of our clinical trial in house dust mite-induced allergic rhinitis is encouraging news for the many patients who continue to suffer with the symptoms caused by house dust mite allergy, and supports our ambition to provide a global therapy for the important US, China and EU markets. Based on the unique triple-combination of our allergoids, and the adjuvant system MPL and MCT we bel...